Qualigen Therapeutics, Inc. announced that it has entered into a Securities Purchase Agreement with returning investor, Alpha Capital Anstalt to issue an 8% Convertible Debenture in the principal amount of $550,000 and to issue a 5-year common stock purchase warrant to purchase 900,016 shares of common stock of the company at an exercise price of $0.26 per share for the gross proceeds of $550,000 on February 26, 2024. The Debenture would have a maturity date of December 31, 2024 and would be convertible, at any time, and from time to time, at investor?s option, into shares of common stock of the Company, at $0.6111 per share, subject to adjustment as described in the Debenture. The Debenture would accrue interest on its outstanding principal balance at the rate of 8% per annum, which would be payable at maturity.